Fiche société
Corestemchemon, Inc.
Traitements, essais et publications liés.
Traitements4programmes
Essais2liés
Publications6liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| LenzumestrocelALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment. | Sclérose latérale amyotrophique | Phase 3 | À vérifier | South Korea | À vérifier |
| RiluzoleDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Parkinson, Sclérose latérale amyotrophique | Phase 3 | À vérifier | South Korea | À vérifier |
| RiluzoleThe purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate. | Parkinson | Phase 3 | Neuroprotection | United Kingdom | À vérifier |
| LenzumestrocelALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment. | Sclérose latérale amyotrophique | Phase 3 | À vérifier | South Korea | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Lenzumestrocel | Sclérose latérale amyotrophique | Phase 3 | NCT04745299 | ALSummit — Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | COMPLETED |
| Riluzole | Parkinson | Phase 3 | NCT00211224 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | TERMINATED |
Publications
6| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Lenzumestrocel | Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. | Trials | ||
| Lenzumestrocel | Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study. | Frontiers in aging neuroscience | ||
| Riluzole | Prescribing and monitoring of riluzole in amyotrophic lateral sclerosis: a retrospective cohort study from Health New Zealand - Te Whatu Ora Waitaha Canterbury. | The New Zealand medical journal | ||
| Riluzole | Introducing Borsantrazole: A Trifunctional Boron-Based Pyrazole That Extends the Lifespan of Amyotrophic Lateral Sclerosis Mice. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | ||
| Riluzole | Huoling Shengji granule in amyotrophic lateral sclerosis: A multicenter, randomized, double-blind, riluzole-controlled trial. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | ||
| Riluzole | Nose-to-brain delivery of riluzole-loaded nanoemulsion in a controlled cortical impact-induced traumatic brain injury: Insights fromIn vitro,Ex vivo, andIn vivostudies. | Colloids and surfaces. B, Biointerfaces |